 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...2526272829303132333435...858859» |
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (clinicaltrials.gov) - Oct 3, 2024
P1/2, N=184, Recruiting, Sponsor: Amgen
Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
- || Tavneos (avacopan) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) (clinicaltrials.gov) - Oct 3, 2024
P1, N=13, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Mar 2026 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024
- || Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Review, Journal: Small molecule-based targeted therapy in liver cancer. (Pubmed Central) - Oct 3, 2024
To date, small-molecule-based targeted therapies are highly recommended (first line: sorafenib and lenvatinib; second line: regorafenib and cabozantinib) by current the clinical guidelines of the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network...In fact, the known small molecule-based therapies still have limited clinical benefits to liver cancer patients. Therefore, we analyze the current status and give our ideas for the urgent issues and future directions in this field, suggesting the clues for novel techniques in liver cancer treatment.
- | AMG 900 / Amgen, Estybon (rigosertib) / Traws Pharma, SymBio Pharma, Knight Therap
Journal: The construction of a prognostic model by apoptosis-related genes to predict survival, immune landscape, and medication in cholangiocarcinoma. (Pubmed Central) - Oct 3, 2024
Therefore, we analyze the current status and give our ideas for the urgent issues and future directions in this field, suggesting the clues for novel techniques in liver cancer treatment. Our project suggested that the prognostic model with apoptotic features can effectively predict prognosis in CCA patients, proffering prognostic biomarkers and potential therapeutic targets for CCA patients.
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease. (Pubmed Central) - Oct 3, 2024
Teprotumumab introduction increased TED therapy evaluations, yet not all received recommended treatment due to safety concerns or accessibility issues. Enhancing collaborative care, medication accessibility, and adverse effect management is crucial.
- | Prolia (denosumab) / Amgen
Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - Oct 3, 2024
A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.
- | Imdelltra (tarlatamab-dlle) / Amgen
FDA event, Journal: 'Tarlatamab's FDA approval: shaping the future of cancer therapy'. (Pubmed Central) - Oct 3, 2024
These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy. No abstract available
- || Stivarga (regorafenib) / Bayer
P2 data, Journal, Checkpoint inhibition, Metastases: Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial. (Pubmed Central) - Oct 3, 2024
The incidence of adverse reactions was 27/29 (93.1%), and the incidence of grade III/IV adverse reactions was 5/29 (17.2%). The combination of chemotherapy, regorafenib, and immune checkpoint inhibitors as a first-line treatment for patients with advanced BTC may has good anti-tumor efficacy without causing serious adverse reactions, and can significantly improve the long-term prognosis.
- | Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Journal: Crinkle-Cut Coronary Arteries in a Patient With Granulomatosis With Polyangiitis. (Pubmed Central) - Oct 3, 2024
Cardiac involvement in GPA is often subclinical and if clinically significant has been rarely reported, even less so as an initial presentation. We describe the case of a 44-year-old man who presented with what appeared to be inferior ST-segment elevation myocardial infarction and was found to have small vessel vasculitis of the coronary arteries with associated myocarditis as a presenting manifestation of GPA, which was ultimately treated with steroids, rituximab, and avacopan.
- | Tavneos (avacopan) / Amgen
Journal, Real-world evidence, Real-world: The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. (Pubmed Central) - Oct 3, 2024
We describe the case of a 44-year-old man who presented with what appeared to be inferior ST-segment elevation myocardial infarction and was found to have small vessel vasculitis of the coronary arteries with associated myocarditis as a presenting manifestation of GPA, which was ultimately treated with steroids, rituximab, and avacopan. The combination of avacopan in clinical practice presents a good safety profile and provides added value by contributing to the control of AAV activity, increase GFR, and removal of steroids.
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Oct 3, 2024
P1, N=188, Recruiting, Sponsor: Amgen
The combination of avacopan in clinical practice presents a good safety profile and provides added value by contributing to the control of AAV activity, increase GFR, and removal of steroids. Trial completion date: Nov 2027 --> Apr 2028 | Trial primary completion date: Nov 2025 --> May 2026
- || bempikibart (ADX-914) / Q32 Bio
Enrollment closed: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Oct 3, 2024
P2, N=102, Active, not recruiting, Sponsor: Q32 Bio Inc.
Trial completion date: Nov 2027 --> Apr 2028 | Trial primary completion date: Nov 2025 --> May 2026 Recruiting --> Active, not recruiting
- | captisol-enabled melphalan / Generic mfg.
Trial completion date, Trial primary completion date: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. (clinicaltrials.gov) - Oct 2, 2024
P1, N=46, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- |||||| Ibrance (palbociclib) / Pfizer
New trial: ROSIE: A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia (clinicaltrials.gov) - Oct 2, 2024
P=N/A, N=1128, Completed, Sponsor: Pfizer
- | Prolia (denosumab) / Amgen
Journal: The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients. (Pubmed Central) - Oct 2, 2024
If the perceived benefits are similar, we recommend using bisphosphonates as first-line therapy in children while reserving denosumab for refractory cases. Future studies will help determine long-term side effects and differences in efficacies of these medications.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Progression of multiple vertebral fractures after Denosumab discontinuation under treatment with Romosozumab. A case-report. (Pubmed Central) - Oct 2, 2024
We believe that treatment with Rmab might not be enough to prevent this phenomenon. Treatment with Dmab or possibly combination treatment with Dmab and Rmab could be another treatment option.
- || Review, Journal: Targeted therapies for uveitis in spondyloarthritis: a narrative review. (Pubmed Central) - Oct 2, 2024
Mixed results have been demonstrated with interleukin-17 antagonists (secukinumab) and interleukin-12/interleukin-23 antagonists (ustekinumab) in cases of failure of TNFis...Although SpA-related uveitis is typically managed with conventional local and/or systemic treatments, these biological/targeted therapies may provide avenues to control both the underlying SpA and uveitis manifestations. Thus, a close collaboration between patients, rheumatologists, internists, and ophthalmologists is needed to optimally manage ocular inflammation in SpA.
- || Vectibix (panitumumab) / Amgen
Clinical, P2 data, Journal: Targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer - a phase II study. (Pubmed Central) - Oct 2, 2024
P2
Thus, a close collaboration between patients, rheumatologists, internists, and ophthalmologists is needed to optimally manage ocular inflammation in SpA. This study met its primary endpoint (pCR/RCB-I=30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of neoadjuvant therapy in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial.
- ||| ivabradine / Generic mfg.
Journal, Adverse events, Real-world evidence, Real-world: Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database. (Pubmed Central) - Oct 2, 2024
This study provides important information for maximizing the usage of ivabradine, increasing its efficacy, and reducing any possible negative effects. The actual clinical use of the medication will be greatly aided by this knowledge.
- | Ibrance (palbociclib) / Pfizer, Lynparza (olaparib) / Merck (MSD), AstraZeneca, Aliqopa (copanlisib) / Bayer
Journal: Characterization of Anticancer Drug Protomers Using Electrospray Ionization and Ion Mobility Spectrometry-Mass Spectrometry. (Pubmed Central) - Oct 2, 2024
Ion mobility-mass spectrometry and density functional theory revealed that these compounds generate isomers during ionization (protomers) due to the presence of multiple protonation sites within their chemical structures. Our work has implications for understanding the solution- and gas-phase chemistry of these molecules during spray-based ionization processes.
- | ivabradine / Generic mfg.
Journal: Postural orthostatic tachycardia syndrome after radiofrequency catheter ablation in the atrioventricular junction-An uncommon and often unrecognized complication. (Pubmed Central) - Oct 2, 2024
Our work has implications for understanding the solution- and gas-phase chemistry of these molecules during spray-based ionization processes. No abstract available
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Review, Journal: Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management. (Pubmed Central) - Oct 2, 2024
Adverse effects, comparative effectiveness with other osteoporotic agents, and challenges in sequential therapy are also discussed, providing insights for informed decision-making by physicians, particularly in the context of pre-treatment considerations. Additionally, the review examines global prescribing guidelines and highlights challenges associated with romosozumab utilization in special patient subgroups, aiming to optimize its clinical use.
- | Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Biomarker, Clinical, Retrospective data, Journal: Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study. (Pubmed Central) - Oct 2, 2024
Conversely, with romosozumab, the levels of bone formation markers increased transiently at 6 months before returning to baseline, whereas bone resorption markers significantly decreased at both time points. Romosozumab demonstrated significantly superior effects over denosumab in improving BMD, especially of the lumbar spine, suggesting that romosozumab can be used for treating male osteoporosis.
- Blincyto (blinatumomab) / Astellas, Amgen
USE OF BLINATUMOMAB TO ACHIEVE REMISSION AND CONSOLIDATION WITH HAPLOIDENTICAL TRANSPLANT WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CHILDREN WITH REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA. () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1476;
Every patient received triple intrathecal with methotrexate, cytarabine and hydrocortisone, two weeks after each Blinatumomab cycle. Blinatumomab proved to be effective to get complete remission as a bridge therapy for children with refractory or relapse pre-B ALL Haploidentical transplantation demonstrated to be an accessible and efficient source to achieve survival of more than 60%.
- Blincyto (blinatumomab) / Astellas, Amgen
AN INITIAL EXPERIENCE OF BLINATUMOMAB'S ADMINISTRATION IN PAKISTANI CHILDREN WITH RELAPSED AND REFRACTORY LEUKEMIA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1427;
Blinatumomab achieved MRD remission in majority of our patients and was generally well tolerated, with the most common side effect being CRS grade 1. It effectively salvaged the majority of patients, resulting in good overall survival.
- Blincyto (blinatumomab) / Astellas, Amgen
PRIOR BLINATUMOMAB USE AND CAR-T CELL THERAPY OUTCOMES IN CHILDREN AND YOUNG ADULTS WITH REFRACTORY/RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1302;
The results of our meta-analysis suggest that prior Blinatumomab use might not have a significant clinical impact on CAR-T cell therapy outcomes. Still, randomized studies and a bigger cohort comparing both groups are needed to further assess this matter.
- Blincyto (blinatumomab) / Astellas, Amgen
REAL-WORLD ADMINISTRATION OF BLINATUMOMAB: CLINICAL AND IMPLEMENTATION RESULTS FROM A HYBRID EFFECTIVENESS-IMPLEMENTATION TYPE 2 STUDY IN PEDIATRIC PATIENTS () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1141;
Successful implementation is a prerequisite for clinical effectiveness. Hybrid-type studies merging implementation and effectiveness outcomes data provide a more thorough demonstration of local value to patients and are critical to support sustainability for novel therapy translation
- topotecan / Generic mfg., cyclophosphamide / Generic mfg.
CYCLOPHOSPHAMIDE-TOPOTECAN: A PROMISING SALVAGE REGIMEN FOR RELAPSED PEDIATRIC SOLID CANCERS () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1077;
Hybrid-type studies merging implementation and effectiveness outcomes data provide a more thorough demonstration of local value to patients and are critical to support sustainability for novel therapy translation Cyclophosphamide was administered intravenously at a dose of 250mg/m
- Blincyto (blinatumomab) / Astellas, Amgen
BLINATUMOMAB ADVERSE EFFECTS IN CHILDREN AND ADOLESCENTS WITH CD19+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION () - Oct 2, 2024 - Abstract #SIOP2024SIOP_985;
We observed a low severity of CRS in this cohort, which may be due to low tumor burden at the moment blinatumomab was applied, or to the aggressive prophylaxis used to prevent this AE or both. We confirm the low frequency of severe infections associated with this type of rescue, facilitating SCT.
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Looking Past the Interference: Toddler with Persistent Fever, Rash, and Lymphadenopathy (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_657;
We confirm the low frequency of severe infections associated with this type of rescue, facilitating SCT. This case highlights the importance of the timely identification of atypical pathogens, recognition of immunodeficiencies in patients, and connection with sub-specialty services for appropriate highly specialized treatment.
- Nplate (romiplostim) / Amgen
A Rare Cause of Short-Rib Thoracic Dysplasia in a Neonate (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_636;
While many conditions in the differential are mainly skeletal disorders, SDS has multisystem involvement that can be life-threatening if not caught early. A high index of suspicion is necessary to recognize this condition in the neonatal population.
- Hetronifly (serplulimab) / Fosun Pharma, Stivarga (regorafenib) / Bayer
Serplulimab in combination with regorafenib and hepatic artery bicarbonate infusion on the third-line treatment in advanced colorectal cancer patients with liver metastasis: study protocol of a single-arm, single-center phase II study () - Oct 2, 2024 - Abstract #CSCO2024CSCO_1674;
- Ibrance (palbociclib) / Pfizer
A Real-world study of palbociclib combined with endocrine therapy as the initial treatment compared with post-chemotherapy maintenance therapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer () - Oct 2, 2024 - Abstract #CSCO2024CSCO_1564;
- Ibrance (palbociclib) / Pfizer, inavolisib (GDC-0077) / Roche
Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 randomized trial primary and additional analys (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_417;
A high index of suspicion is necessary to recognize this condition in the neonatal population. Study group: [Organizing Committee]
- || Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open: DeLLphi-307: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (clinicaltrials.gov) - Oct 2, 2024
P2, N=30, Recruiting, Sponsor: Amgen
Study group: [Organizing Committee] Not yet recruiting --> Recruiting
- ||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment closed: TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=92, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Stivarga (regorafenib) / Bayer
P2 data, Journal, Metastases: Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma. (Pubmed Central) - Oct 1, 2024
We hypothesize that TKI efficacy may be reliant upon an interplay between kinase inhibition and the ACC immune microenvironment, while programs promoting cell cycle progression may contribute to TKI resistance. These observations suggest that trials evaluating CDK4/6 inhibition plus a VEGFR-TKI should be considered.
- | Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene
Retrospective data, Journal, Combination therapy, Metastases: Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123). (Pubmed Central) - Oct 1, 2024
These observations suggest that trials evaluating CDK4/6 inhibition plus a VEGFR-TKI should be considered. THCQ and TP are not effective in patients with advanced PDAC harboring KRAS mutations or alterations in MAPK/CDKN2A/B.
- | Prolia (denosumab) / Amgen
Journal: Calcinosis Universalis Secondary to Silicone Injections in a Patient With HIV and Chronic Kidney Disease: A Case Report of Silicone-Induced Hypercalcemia. (Pubmed Central) - Oct 1, 2024
Initial management included intravenous (IV) fluids and one dose of IV pamidronate, which resulted in reduced calcium levels during the admission. Subsequent management included outpatient follow-up with endocrinology during which denosumab was prescribed...If suspected, the use of imaging techniques (e.g. positron emission tomography (PET) scans or MRI) may help
- ||| efavaleukin alfa (AMG 592) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Oct 1, 2024
P2, N=224, Active, not recruiting, Sponsor: Amgen
Subsequent management included outpatient follow-up with endocrinology during which denosumab was prescribed...If suspected, the use of imaging techniques (e.g. positron emission tomography (PET) scans or MRI) may help Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Feb 2025 --> Oct 2024
- ||| divarasib (RG6330) / Roche, Lumakras (sotorasib) / Amgen
Trial completion date: Krascendo 1: A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 1, 2024
P3, N=320, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Feb 2025 --> Oct 2024 Trial completion date: Jul 2028 --> Sep 2029
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Trial completion date, Trial primary completion date: Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=100, Completed, Sponsor: Cairo University
Trial completion date: Jul 2028 --> Sep 2029 Recruiting --> Completed | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Aug 2024
- ||| daxdilimab (HZN-7734) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) (clinicaltrials.gov) - Oct 1, 2024
P2, N=12, Active, not recruiting, Sponsor: Amgen
Recruiting --> Completed | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Aug 2024 Recruiting --> Active, not recruiting | N=96 --> 12 | Trial completion date: May 2027 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Mar 2025
- | Ibrance (palbociclib) / Pfizer
Trial completion date: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 1, 2024
P1, N=26, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=96 --> 12 | Trial completion date: May 2027 --> Oct 2025 | Trial primary completion date: Oct 2026 --> Mar 2025 Trial completion date: Jan 2023 --> Dec 2024
- | AMB-05X / AmMax
New P2 trial: Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov) - Sep 30, 2024
P2, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| rocatinlimab (KHK4083) / Amgen
Enrollment change: A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (clinicaltrials.gov) - Sep 30, 2024
P3, N=150, Recruiting, Sponsor: Amgen
Trial completion date: Jan 2023 --> Dec 2024 N=100 --> 150
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov) - Sep 30, 2024
P4, N=130, Completed, Sponsor: German Breast Group
N=100 --> 150 Recruiting --> Completed | Trial completion date: Mar 2023 --> Aug 2024 | Trial primary completion date: Mar 2023 --> Aug 2024
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal: Effectiveness and safety of alirocumab and evolocumab for hypercholesterolemia in a population with high cardiovascular risk. (Pubmed Central) - Sep 30, 2024
PCSK9i were used according to CatSalut criteria in three out of four cases. In this high-risk population, incidence of cardiovascular events was similar to that in clinical trials.
- | Vectibix (panitumumab) / Amgen
Journal: Fluidic Interface for Surface-based DNA Origami Studies. (Pubmed Central) - Sep 30, 2024
These surfaces were used to recruit and activate the epidermal growth factor receptor (EGFR) through clustering in the membranes of living cancer cells (MCF-7) using an antagonistic antibody (Panitumumab). The activation was quantified depending on the interligand distances of the EGFR-targeting antibody.
- || trebananib (AMG 386) / Amgen, Keytruda (pembrolizumab) / Merck (MSD)
P1 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer. (Pubmed Central) - Sep 30, 2024
P1
After development of acquired resistance, biopsy of one patient's KRAS wild-type, ERBB2 amplified tumor showed a substantial decline in tumor-associated T cells and an increase in immunosuppressive intratumoral macrophages. Future studies are needed to carefully assess whether clinicogenomic features, such as lack of liver metastases, ERBB2 amplification, and left-sided tumors, can predict increased sensitivity to PD1 immunotherapy combinations.